Cancer history

Contraindications Allergy to peanut oil (oral), breast cancer, history of active cerebral apoplexy, thromboembolic disorders or thrombophlebitis, severe hepatic dysfunction, undiagnosed vaginal bleeding... 

Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer history and rationale. Urol Oncol. 2006 24 250-253. 

Thus, attention can be drawn to such therapies as megadoses of vitamin C, Essiac tea, shark cartilage, and elimination of parasitic invaders. More will be further described in the subsequent sections. We particularly recall the works of Ralph W. Moss (1992, 1998), Cancer Therapy The Independent Consumer s Guide to Non-Toxic Treatment and Prevention and Herbs against Cancer History and Controversy, both of which furnish the pros and cons. 

Of special motion is Ralph Moss s informative Herbs Against Cancer History and Controversy, which has chapt on diletmnas in other countries as well as the United States. It does not try to be all inclusive, not having a chapter on either laetrile or creosote birsh (chaparral), for irrstance, which may or may not be referred to as herbs. 

Moss, R.W. 1998. Herbs Against Cancer History and Controversy. Brooklyn, NY Equinox... 

After the cancer history with BCG and interferon, all other tumor immunotherapy measures emerged outside the MDACCC. It was combination chemotherapy that continued to receive a disproportionately overwhelming support at the DDT of MDACC and elsewhere. Discoveries made outside the MDACCC (doxorubicin cytosine arabinoside, or cytarabine) received prompt supportive funds to be tested in clinical trials at the DDT of MDACCC, while support for tumor immunotherapy was left way behind. Early efforts at it failed to receive any support from the NCI/NIH at the DM through the entire 1970s. Cancer chemotherapy proved itself to be a remission-inducer modality of treatment, and thus it was supported in full. The pharmaceutical industry started to pay consultation fees to academic physician principal investigators of chemotherapy protocols at academic institutions. Emil Frei HI, the head of the DDT, published in Cancer Research in 1985 his famous paper Curative cancer chemotherapy , appearing after he left M.D. Anderson for Dana-Farber [2287]. 

Olson JS. Making Cancer History. Baltimore Johns Hopkins University Press 2009. 2291a. Huang ME, Ye YC, Wang ZY. Treatment of 4 APL patients with all-transretinoic acid. 

---